Comparison of Different Treatment Strategies Combating COVID-19 in Pakistan
Pakistan Armed Forces Medical Journal
; 72(5):1752-1756, 2022.
Article
in English
| Scopus | ID: covidwho-2146765
ABSTRACT
Objective:
To compare different treatment strategies for patients of COVID-19 in Pakistan. StudyDesign:
Retrospective longitudinal study. Place and Duration of Study Abbas Medical Hospital, Muzaffarabad Pakistan, during Apr 2021.Methodology:
One hundred and twenty, COVID-19-positive patients between 31-45 years of age were admitted to Abbas hospital after carrying out the rRT-PCR test. Group-A was administered Azithromycin, while Group-B was treated with Azithromycin in combination with Hydroxychloroquine. Group-C was given a combination of oral Ivermectin and Doxycy-cline, and Group-D was treated with Lopinavir. Diagnostic tests include rRT-PCR, blood parameters such as creatinine, random blood sugar, alanine aminotransferase, complete blood count, ECG, chest x-ray and blood biomarkers including procalcitonin, C-reactive protein, lactate dehydrogenase and ferritin were performed at Day 1, 5, 7, 14 and 30.Results:
Patients treated with Azithromycin revealed the highest recovery of about (77.80%) among COVID-19 patients, followed by the combination of Azithromycin and Hydroxychloroquine which was (65.56%), the combination of Ivermectin and Doxycycline was (19.63%), and Lopinavir was (9.06%) displayed minimum potency in recovering the COVID-19 positive patients (p-value <0.001).Conclusions:
Azithromycin was most effective in helping patients recover from COVID-19, followed by a combination of azithromycin and Hydroxychloroquine. Patients who recovered after treatment with Ivermectin Doxycycline were lower, followed by those who recovered with Lopinavir only. © 2022, Army Medical College. All rights reserved.
Full text:
Available
Collection:
Databases of international organizations
Database:
Scopus
Language:
English
Journal:
Pakistan Armed Forces Medical Journal
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS